Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 335

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 335
---
 shall have received tax rulings in form and substance reasonably acceptable to NLS; and •Kadimastem shall have provided evidence reasonably satisfactory to NLS that Kadimastem Ordinary Shares shall have been delisted from the TASE effective as of the Effective Time. Unless waived by Kadimastem, the obligations of Kadimastem to consummate the Merger are subject to the satisfaction of the following additional conditions: •the representations and warranties of NLS and Merger Sub shall be true and correct as of the Closing (subject to Material Adverse Effect); •NLS and Merger Sub shall have performed in all material respects their respective obligations and complied in all material respects with their respective covenants and agreements under the Merger Agreement required to be performed or complied with on or prior to the date of the Closing; •the absence of any Material Adverse Effect with respect to NLS, taken as a whole, since the date of the Merger Agreement which is continuing and uncured; •NLS shall have paid off, redeemed or satisfied all of its Vendor Indebtedness; •NLS shall have terminated the employment and engagement of all of its employees and consultants and paid or otherwise satisfied all back pay, severance or termination pay, vacation pay and all other liabilities in respect of all such employment and engagement; •Nasdaq shall have rescinded its notice to NLS as to NLS’s failure to satisfy Nasdaq criteria for listing and trade thereon. On October29, 2024, the Company updated that NLS announced on October28, 2024, that it had received final approval from Nasdaq confirming that it meets the requirements to continue trading; •NLS shall have at least $600,000 in gross funds (including cash in any of its bank accounts); •The (i) directors of NLS immediately prior to the Effective Time shall have resigned from their positions (other than Mr. Zwyer), (ii) officers of NLS immediately prior to the Effective Time shall have resigned from their positions (other than Mr. Konofal who shall remain in a part -timeposition with NLS), (iii) the executive officers of Kadimastem immediately prior to the Effective Time shall be appointed as executive officers of NLS, and (iv) NLS shall have convened the shareholder meeting and shall have elected Kadimastem’s Board members as members of the NLS Board, effective as of the Effective Time; and •NLS Common Shares shall remain listed on